By Julie Steenhuysen CHICAGO, Nov 7 (Reuters) - An experimental Novartis drug designed to treat a genetic cause of heart ...

Advocates are sounding the alarm on social media as they learn from their doctors that Novartis has received reports of ...

Novartis AG is largely abandoning an experimental drug analysts once considered a potential blockbuster after a study found ...

The occurrence of cancer in nine recipients — two of which involved evidence that a viral delivery tool integrated into ...

Novartis (NVS) is ending the development of heart drug pelacarsen discovered by Ionis Pharmaceuticals (IONS) after a ...

ZURICH, Nov 6 (Reuters) - The US Food and Drug Administration said on Friday it was investigating a risk of neoplasia, or ...

A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.

Children taking Novartis’s Zolgensma gene therapy for the deadly condition of spinal muscular atrophy have developed tumors, ...

Novartis has lifted the lid on data from its failed cardiovascular outcomes trial, reporting a total absence of efficacy that ...

Novartis has reported nine cases of cancer in children worldwide who had previously been treated with the gene therapy ...

Novartis has confirmed a number of new cases of tumors that developed in children treated with its gene therapy Zolgensma ...

Novartis has confirmed nine instances—seven of them newly disclosed—in which tumors have developed in children treated with its marketed spinal muscular atrophy gene therapy Zolgensma® (onasemnogene ...